NCT05494736View on ClinicalTrials.gov

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

MK-8527

MK-8527 capsule taken by mouth.

Trial Locations (4)

2092

Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0002), Johannesburg

7925

Desmond Tutu Health Foundation ( Site 0001), Cape Town

9301

Josha Research ( Site 0003), Bloemfontein

Unknown

ARENSIA Exploratory Medicine-Institutul National de Boli Infectioase Matei Bals ( Site 0004), Bucharest

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY